Can Regeneron Pharmaceuticals (REGN) Stock Reach $850?

Key Takeaways

• The central $850 price target is the arithmetic mean of roughly 27 to 30 current analyst price targets reviewed from multiple data providers, which report an average between about $851 and $856.
• At the most recent close of $735.20, reaching $850 would require a gain of about 15.6% from current levels.
• Individual analyst targets span a wide range from roughly $730 to $1,030, reflecting genuine disagreement about the company's growth trajectory.
• The strongest supports are surging Dupixent sales, uptake of the higher-dose Eylea HD, and an expanding oncology pipeline.
• The biggest risks are Eylea biosimilar competition, the failure of the fianlimab/LAG-3 melanoma trial, and product concentration.

Analyst Price Targets and Consensus View

Regeneron Pharmaceuticals, Inc. is a Tarrytown, New York-based biotechnology company best known for the eye-disease drug Eylea and the Sanofi-partnered immunology therapy Dupixent. REGN carries broad analyst coverage, with a consensus rating generally described as "Buy" or "Overweight." Data providers report an average analyst price target of approximately $851 to $856, based on 27 to 30 published targets, with a low near $730 and a high of about $1,030.

The $850 central target used here is a rounded arithmetic mean of those verified individual targets, not a published official consensus. Targets differ sharply because analysts weigh the same facts differently. Bullish firms such as J.P. Morgan ($900), Jefferies ($930), and Argus ($850, upgraded to Buy from Hold on October 1, 2026) emphasize Dupixent's momentum and pipeline optionality. More cautious shops, including Wells Fargo ($750), Citi ($740), RBC Capital ($737), and Bernstein ($756), reflect concerns about Eylea erosion and pipeline setbacks.

Current Market Position and Path Toward the Target

At its most recent close, REGN traded at $735.20. Reaching the $850 central target implies upside of roughly 15.6%, a substantial but not extreme move for a large-cap biotech with a market value near $78 billion. The path toward the target depends on whether Dupixent's growth and newer launches can continue to offset an accelerating decline in Eylea, which faces U.S. biosimilar competition expected to intensify in the second half of 2026. The shares pulled back sharply in early October, falling nearly 5% in one session to $729.05 before stabilizing around $735, highlighting how sensitive the stock remains to news flow.

What Could Support a Move Toward the Target

Dupixent is the clearest driver. Argus cited second-quarter sales growth of about 38% to roughly $6 billion in its upgrade, and the drug continues to expand across indications including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). Eylea HD has shown strong uptake, helping Regeneron mitigate the impact of falling Eylea sales. The oncology portfolio is broadening as well, with Libtayo label expansions and approvals for Lynzyfic in multiple myeloma and Ordspono in lymphoma. The balance sheet is a further cushion, with roughly $18.9 billion in cash and marketable securities against modest debt, giving the company flexibility to invest in its pipeline.

What Could Prevent the Target From Being Reached

The principal obstacle is Eylea, still a major revenue contributor that is declining as Roche's Vabysmo and compounded alternatives take share and as multiple U.S. biosimilars launch. Regeneron has said it expects Eylea sales to decline further in 2026. The failure of the Phase 3 fianlimab/LAG-3 melanoma trial earlier in the year trimmed the oncology thesis and triggered a series of target reductions and downgrades. Product concentration remains a structural concern, with a large portion of profits tied to Dupixent and Eylea, and securities litigation related to the fianlimab setback could weigh on sentiment even if the underlying business performs.

Technical Levels and Market Structure

Regeneron has traded in a wide 52-week band from roughly $541 to about $859. The recent decline left the stock below its prior highs, with near-term support around the $726 to $729 area that held in early October and more durable support in the low $700s. On the upside, the $800 round-number level and the prior high near $859 represent the main resistance zones that would need to be cleared for the stock to approach the $850 central target. A sustained move back above the high $700s would signal renewed buying interest.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms apply different frameworks and timelines. The most important near-term events are Regeneron's next quarterly earnings release, expected around late October 2026, and management commentary on Dupixent and Eylea HD trends. Investors should also track Eylea biosimilar launch dynamics, any regulatory or clinical updates across the oncology and immunology pipeline, and further analyst target revisions, which have been volatile in both directions. Interest-rate moves and broader healthcare-sector sentiment can also influence how much investors are willing to pay for a biotech's future earnings.

AI Daily Buy/Sell Signals

For traders seeking a data-driven complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The platform is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. Because signals update as conditions evolve, they can provide a useful, real-time view of momentum alongside the longer-horizon perspective embedded in analyst price targets.

Final Assessment

The question of whether REGN can reach $850 rests on a balance of powerful growth drivers and meaningful headwinds. The target, derived as the average of current analyst price targets, sits roughly 15.6% above the latest price and within the upper portion of a very wide $730-to-$1,030 range. Dupixent's momentum, Eylea HD adoption, and pipeline breadth support the bullish case, while Eylea biosimilar erosion, the fianlimab setback, and concentration risk argue for caution. With analyst opinion split and the shares recently under pressure, the next earnings report and Dupixent and Eylea trends will be decisive in determining whether the stock builds a credible path toward $850. No analyst target is a guarantee, and investors should weigh the full range of outcomes before acting.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations